View Older Stories View More Recent Stories
-
H.C. Wainwright cuts Sarepta (SRPT) price target to $0, reiterates Sell rating
-
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Wells Fargo Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorgan
-
Sarepta Therapeutics (SRPT) options active amid large share price sell off
-
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)
-
William Blair Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)
-
Mizuho Downgrades Sarepta Therapeutics (SRPT) to Neutral
-
Leerink Partners Downgrades Sarepta Therapeutics (SRPT) to Market Perform
-
Deutsche Bank Downgrades Sarepta Therapeutics (SRPT) to Sell
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
Sarepta receives FDA request to halt ELEVIDYS shipments for some patients
-
Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'
-
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
FDA to Request Sarepta (SRPT) to Voluntarily Stop All Shipments of Elevidys - Reuters
-
FDA Investigating Whether Sarepta's (SRPT) Elevidys Should Stay On The Market - Bloomberg
-
Sarepta Therapeutics (SRPT) PT Lowered to $50 at BMO Capital Following Mangement Call
-
Needham Downgrades Sarepta Therapeutics (SRPT) to Hold
-
SRPT Investors Have the Opportunity to Lead the Sarepta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
Sarepta Therapeutics (SRPT) CEO: did not disclose patient death on June 16 call as "It was neither material nor central to the topics at hand" - Conference Call
-
Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'
-
Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)
-
Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
William Blair on Sarepta Therapeutics (SRPT): 'we continue to view the stock’s near-term upside potential as limited'
-
Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
Sarepta shares tumble after report of patient death in early-stage trial
-
Sarepta Therapeutics (SRPT) PT Raised to $28 at TD Cowen
-
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Needham Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
After-hours movers: United Airlines, Sarepta Therapeutic, MP Materials
-
Sarepta cuts 36% of workforce, expects $400M in annual savings
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
SRPT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
Faruqi & Faruqi Notifies Sarepta Therapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT
-
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
Sarepta Therapeutics (SRPT) PT Lowered to $28 at JPMorgan
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
SRPT INVESTOR ALERT: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
-
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
